Celon Pharma S.A. (WSE:CLN)

Poland · Delayed Price · Currency is PLN

22.05

-0.65 (-2.86%)

Mar 2, 2026, 1:28 PM CET

-3.08% (1Y)

Market Cap	1.22B
Revenue (ttm)	225.60M
Net Income (ttm)	-122.39M
Shares Out	53.86M
EPS (ttm)	-2.36
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	13,212
Average Volume	13,194
Open	21.80
Previous Close	22.70
Day's Range	21.50 - 22.20
52-Week Range	18.50 - 28.65
Beta	0.68
RSI	53.29
Earnings Date	Apr 22, 2026

About Celon Pharma

Celon Pharma S.A., an integrated pharmaceutical company, engages in the research, manufacture, and marketing of pharmaceutical products and preparations. It offers drugs to treat cancers, neurological diseases, diabetes, and other metabolic disorders. The company was founded in 2002 and is based in Lomianki, Poland. Celon Pharma S.A. operates as a subsidiary of Glatton Sp. z o.o. [Read more]

Industry Drug Manufacturers - Specialty & Generic

Sector Healthcare

Founded 2002

Employees 566

Stock Exchange Warsaw Stock Exchange

Ticker Symbol CLN

Full Company Profile

Financial Performance

In 2024, Celon Pharma's revenue was 205.55 million, a decrease of -4.25% compared to the previous year's 214.66 million. Losses were -34.45 million, 22.5% more than in 2023.

Financial Statements

News

Strong Proof-of-Concept Data from Phase 2 Trial of PDE10A Inhibitor (CPL'36), a Novel Once-Daily Treatment of Levodopa-Induced Dyskinesia in Parkinson's Disease

Statistically significant improvement in primary endpoint (UDysRS total scale) at Week 4 and positive benefit in the key secondary endpoint (UDysRS objective subscale), beginning at Day 7 Favorable to...

1 year ago - Benzinga